Teriflunomide Tecfidera LMCE

Inclusion Criteria:

Diagnosed with MS according to McDonald criteria
Age 18-65 years
Relapsing disease course
Expanded Disability Status Scale (EDSS) score of ≤ 5.5
MRI obtained at baseline (medication start date), 12 months, and 24 months
Treated with 14mg of teriflunomide ≥ 3 months or with 240mg of dimethyl fumarate ≥ 3 months to meet inclusion, reflective of recommended dosing on the package label
Clinical information available over the 24 month follow-up
None of the exclusion criteria

Exclusion Criteria:

Diagnosis of non-relapsing MS
Use of experimental drug or investigational procedure during the study period
Pregnancy during study period
Severe hepatic impairment
Relapse within 30 days prior to any of the 3 MRIs
Corticosteroid use within 30 days prior to the MRIs
Teriflunomide patients who have used leflunomide
Pre-baseline use of alemtuzumab, cladribine, rituximab, or mitoxantrone
Any other factor that, in the opinion of the investigator, would make the subject unsuitable for participation